Breast cancer
Destiny Breast - 01 trial | 2020 | HER2+ advanced |
Destiny Breast - 04 | 2022 | HER2+ advanced |
Destiny Breast - 03 | 2022 | HER2+ advanced |
Tailor-X | 2018 | HER2+ perioperative |
Katherine Trial | 2020 | HER2+ perioperative Tx |
PALOMA-3 trial | 2016 | HR+ advanced (CDK 4/6 and PIC3CA) |
PALOMA-2 Trial | 2016 | HR+ advanced (CDK 4/6 and PIC3CA) |
MONARCH 2 trial | 2017 | HR+ advanced (CDK 4/6 and PIC3CA) |
MONARCH 3 trial | 2017 | HR+ advanced (CDK 4/6 and PIC3CA) |
MONALEESA-7 Trial | 2018 | HR+ advanced (CDK 4/6 and PIC3CA) |
MONALEESA-3 trial | 2018 | HR+ advanced (CDK 4/6 and PIC3CA) |
Solar-1 Trial | 2019 | HR+ advanced (CDK 4/6 and PIC3CA) |
MonarchE trial | 2020 | HR+ advanced (CDK 4/6 and PIC3CA) |
PALLAS trial | 2021 | HR+ advanced (CDK 4/6 and PIC3CA) |
ATAC trial | 2002 | HR+ endocrine |
IES trial | 2004 | HR+ endocrine |
ITA trial | 2005 | HR+ endocrine |
NSABP B-33 | 2008 | HR+ endocrine |
BIG 1-98 trial | 2009 | HR+ endocrine |
TEAM trial | 2011 | HR+ endocrine |
ABCG 8 trial | 2012 | HR+ endocrine |
ATLAS trial | 2013 | HR+ endocrine |
ATTOM trial | 2013 | HR+ endocrine |
NCIC CTG MA.27 trial | 2013 | HR+ endocrine |
TEXT trail | 2014 | HR+ endocrine |
Meta-analysis of AI vs TAM in early breast cancer | 2015 | HR+ endocrine |
SOFT trial | 2015 | HR+ endocrine |
MA-17R | 2016 | HR+ endocrine |
FACE trial | 2017 | HR+ endocrine |
IDEAL (BOOG 2006-05) trial | 2018 | HR+ endocrine |
SOLE trial | 2018 | HR+ endocrine |
ABCSG-16 trial (SALSA) trial | 2021 | HR+ endocrine |
NSABP B-06 trial | 2002 | Miscellaneous |
NSABP B-04 trial | 2002 | Miscellaneous |
IMpassion130 | 2021 | TNBC advanced |
ASCENT Trial | 2021 | TNBC advanced |
NSABP-B15 trial | 1990 | TNBC perioperative |
CALGB 9344 trial | 2003 | TNBC perioperative |
CALGB 9741 trial | 2003 | TNBC perioperative |
USORTC-9735 trial | 2009 | TNBC perioperative |
CALGB 40101 trial | 2012 | TNBC perioperative |
CALGB 40603 (Alliance) trial | 2015 | TNBC perioperative |
CREATE-X trial | 2017 | TNBC perioperative |
Keynote-522 | 2020 | TNBC perioperative |
OlympiA trial | 2021 | TNBC perioperative |
TEXT trail
Pagani O et al, NEJM, 2014; PMID: 24881463
HR+ endocrine
Background: included 4690 premenopausal women with HR+ early breast cancer
Arm A: Tamoxifen 20mg daily with ovarian function suppression (OFS)
Arm B: Exemestane 25mg daily with OFS
OFS was achieved by gonadotropin- releasing-hormone (GnRH) agonist triptorelin 3.75mg IM q28d , bilateral oophorectomy, or bilateral ovarian irradiation.
mFollow up: 68mo (~5.6yr)
5-yr DFS: 91.1% vs 87.3% for AI+OFS vs TAM+OFS (HR for disease recurrence, second invasive cancer, or death 0.72, 95%CI 0.60-0.85, P<.001).
Freedom from breast cancer at 5yr: 92.8% vs 88.8% for AI+OFS vs TAM+OFS (HR 0.66, 95%CI 0.55-0.80, P<.001).
mOS: HR, 1.14; 95%CI 0.86-1.51; P=.37
Conclusions: AI + OFS (vs TAM+OFS) is more efficient in decreasing recurrence of breast cancer. Importantly, OFS provides benefit only in high-risk breast cancer patients (Stage II and III, high risk biologic features) especially in women < 35yr old.
Summarized by Veli Bakalov, MD